Clinical trial
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant…
NCT00237172 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00237172 |
|---|---|
| Title | Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) |
| Official title | Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumors |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate |
| Enrollment | 72 |
| Start date | Sep 1, 2002 |
| Primary completion | Jul 1, 2005 |
| First posted | Oct 12, 2005 |
| Last update posted | May 1, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: